Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company

Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability

Fineline Cube Aug 23, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...

Company

3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength

Fineline Cube Aug 23, 2024

3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...

Company

Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy

Fineline Cube Aug 23, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...

Company Drug

Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors

Fineline Cube Aug 23, 2024

Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer

Fineline Cube Aug 23, 2024

Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...

Company Legal / IP

Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion

Fineline Cube Aug 23, 2024

Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...

Company Drug

CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain

Fineline Cube Aug 23, 2024

CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation...

Company Deals

GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets

Fineline Cube Aug 23, 2024

Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...

Company

WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report

Fineline Cube Aug 23, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...

Company Drug

Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China

Fineline Cube Aug 23, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...

Policy / Regulatory

China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages

Fineline Cube Aug 22, 2024

The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply...

Policy / Regulatory

China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration

Fineline Cube Aug 22, 2024

The General Office of the Communist Party of China (CPC) Central Committee and the State...

Company Drug

Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China

Fineline Cube Aug 22, 2024

Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...

Company Drug

BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment

Fineline Cube Aug 22, 2024

BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches

Fineline Cube Aug 22, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...

Company Drug

Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China

Fineline Cube Aug 22, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...

Company Deals

Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership

Fineline Cube Aug 22, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang...

Company Deals

SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research

Fineline Cube Aug 22, 2024

SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...

Company

Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024

Fineline Cube Aug 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded...

Drug

Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline

Fineline Cube Aug 22, 2024

Akeso Biopharma, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 9926),...

Posts pagination

1 … 310 311 312 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.